Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
ALPHARETTA, Ga., Feb. 18, 2016 -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the period ended December 31st, 2015, at the close of the financial markets on March 2, 2016.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 10:00 AM ET, on March 3, 2016. Please refer to the information below for conference call dial-in information and webcast registration.
Conference date: March 3, 2016, 10:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences Fourth Quarter 2015 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera Sciences (NASDAQ:ALIM), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: COCKRELL GROUP 877.889.1972 [email protected] cockrellgroup.com
